Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation reports recurring developments across its global medical technology business, including financial results, investor conference participation, product studies and U.S. regulatory actions. The company’s solutions include hospital technologies, end-to-end plasma collection technologies for plasma centers and products used by blood centers to collect blood components.
Company news frequently centers on the VASCADE MVP and VASCADE MVP XL venous vascular closure systems, the NexSys PCS Plasma Collection System and Persona technology. Updates also cover FDA approvals or 510(k) clearances, clinical evidence supporting device use, earnings releases and presentations, and communications tied to the company’s plasma, blood center and hospital markets.
Haemonetics (NYSE: HAE) is updating its financial reporting segments, moving from three to two reportable segments to align reporting with internal management and resource allocation.
The former Plasma and Blood Center segments will combine into Apheresis, and the Hospital segment will be renamed MedSurg, starting with Q1 fiscal 2027.
Haemonetics (NYSE:HAE) announced that President and CEO Chris Simon will join a fireside chat with investors at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. ET.
A live webcast and 90-day replay will be available via Haemonetics' Investor Relations website.
Haemonetics (NYSE: HAE) announced that its fourth quarter fiscal 2026 results for the period ended March 28, 2026 are posted on the company Investor Relations website. The company will host a live conference call and webcast on May 7, 2026 at 8:00 a.m. ET.
Replay of the call will be available beginning at 11:00 a.m. ET on May 7, 2026 and remain accessible for one year. Earnings release and supplemental presentation are posted and will be referenced during the call.
Haemonetics (NYSE: HAE) announced that President and CEO Chris Simon will speak in a fireside chat at the Bank of America 2026 Healthcare Conference on May 12, 2026 at 8:00 a.m. PT.
According to the company, a live webcast will be available on Haemonetics' Investor Relations website and a replay will be posted within 24 hours and hosted for one year.
Haemonetics (NYSE: HAE) announced publication of a 574‑patient single‑center comparative study showing VASCADE MVP XL achieved higher procedural success and reported 0% bleeding complications in large‑bore venous access closure for electrophysiology procedures. In March 2026 the FDA expanded labeling to cover 10–14F ID and up to 17F OD sheaths.
FDA clearance was supported by the multicenter AMBULATE EXPAND pivotal trial and a 31‑patient ultrasound sub‑study with encouraging early vascular imaging results.
Haemonetics (NYSE: HAE) will publish fourth quarter and fiscal year 2026 results at 6:00 am ET on May 7, 2026. A conference call with investors and analysts is scheduled for 8:00 am ET on May 7, 2026.
Participants can join via teleconference after registration to receive a dial-in number and personalized PIN. A live webcast will be available on Haemonetics' investor relations website and a replay will be accessible for one year starting May 7, 2026 at 11:00 am ET.
Haemonetics (NYSE: HAE) received FDA approval to expand labeling for the VASCADE MVP XL venous vascular closure system to include procedures using 10-14F inner diameter and up to 17F outer diameter procedural sheaths.
Approval relied on the AMBULATE EXPAND trial (77 patients) that showed 0% major and 0% minor access site closure-related complications and a median time to ambulation of 2.4 hours. The device features a 25F disc and 19 mg resorbable collagen and is now cleared for larger PFA and LAAC procedures.
Haemonetics (NYSE: HAE) received FDA 510(k) clearance on Feb 23, 2026 for the NexSys PCS Plasma Collection System with Persona PLUS technology. Persona PLUS is the next generation of Persona and was supported by a prospective, randomized, controlled, multicenter pivotal trial of over 30,000 donations from nearly 3,000 donors.
Trial data showed Persona PLUS delivered a mid-single-digit percent increase in average plasma volume per donation versus Persona, supporting safety and effectiveness for U.S. use.
Haemonetics (NYSE: HAE) said President and CEO Chris Simon will speak in a fireside chat at the Raymond James 47th Annual Institutional Investors Conference on March 2, 2026 at 10:25 a.m. ET.
The event will be available via a live webcast on Haemonetics' Investor Relations site, with a replay posted 12 hours after the event and available for 90 days.
Haemonetics provides hospital and blood-collection technologies and end-to-end plasma collection solutions to improve healthcare outcomes.
Haemonetics (NYSE: HAE) posted its third quarter fiscal 2026 results for the period ended December 27, 2025, on its Investor Relations website.
The company will host a conference call and live webcast at 8:00 a.m. ET on February 5, 2026, with a replay available from 11:00 a.m. ET on February 5, 2026 for one year. Earnings release and a supplemental presentation are posted and will be referenced on the call.